Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06422429
Other study ID # RCT_PI Youtiao
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date March 1, 2025
Est. completion date December 1, 2025

Study information

Verified date January 2024
Source Zhejiang University
Contact Yu Zhang, PHD
Phone 86-0571-88982211
Email yzhang@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to investigate the effects of personalized innovative fritters on the nutritional health of overweight and obese individuals aged 40 to 70 years. The main questions it aims to answer are: - How does consuming personalized innovative fritters affect the nutritional health of overweight and obese individuals? - What is the mechanism underlying the impact of personalized innovative oil bars on nutritional health? Participants will be randomly assigned to one of two groups: a trial group consuming personalized innovative fritters and a control group consuming traditional fritters with equal energy content. Over the course of 6 months, participants will undergo two phases of intervention separated by a two-month washout period. During the intervention, participants will be assessed comprehensively for sensory ratings and nutritional health status through biological indicators, physical examinations, and other relevant measures. Researchers will compare the trial group to the control group to determine if personalized innovative fritters lead to improvements in nutritional health compared to traditional fritters.


Description:

Participants entered the trial with a 1-week equilibration period during which baked and fried foods were prohibited. The test group will consume personalised innovative Youtiao and the control group will uniformly consume traditional Youtiao of equal energy, 45 g 4 times per week for 8 weeks, during which time we will periodically measure biological indicators and collect biological samples to gain insight into the effects of the personalised innovative Youtiao on the participants. After completion of the 8-week intervention, a washout phase is entered. During this phase, participants will no longer ingest the Youtiao to see how they trend after stopping the intervention. Participants then enter the second phase of the trial, where the intervention process described above is continued with appropriate consumption adjustments based on the initial results of the first phase of the intervention.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 150
Est. completion date December 1, 2025
Est. primary completion date September 1, 2025
Accepts healthy volunteers No
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria: - Age between 40-70 years old (women need to be menopausal); - BMI>24 kg/m2; - Consumption of fritters more than once a week. Exclusion Criteria: - history of diabetes mellitus, cardiovascular disease, dyslipidaemia, renal disease, - - liver disease or cancer; - surgical treatment within 3 months; - allergy/intolerance to the study food or any of its ingredients; - breastfeeding or pregnancy; - >10% weight loss in the past 6 months; - smoking or alcohol abuse; - participation in another clinical study within the past 6 months

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Traditional deep-fried Youtiao
45g 4 times a week for 4 months
PI Youtiao
45g 4 times a week for 4 months

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Yu Zhang

Outcome

Type Measure Description Time frame Safety issue
Primary Change in HbA1c The investigators will measure HbA1c in blood samples before and after treatment. 6 months
Primary Change in blood glucose from baseline The investigators will measure fasting plasma glucose levels in blood samples before and after treatment. 6 months
Secondary Change in blood lipids from baseline The investigators will measure Triglycerides (TG), total cholesterol (TC), LDL-C, and HDL-C levels in blood samples before and after treatment. 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05864833 - METabolism After Orthopedic Surgery
Completed NCT02235961 - Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects Phase 1
Completed NCT02918279 - Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity Phase 3
Completed NCT00978393 - A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers Phase 1
Completed NCT03661879 - Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity Phase 1
Completed NCT05024032 - A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) Phase 3
Completed NCT02568306 - A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects Phase 1
Completed NCT00781937 - Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance Phase 3
Completed NCT03223493 - Awareness, Care & Treatment in Obesity Management (ACTION) Study
Completed NCT03308721 - Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity Phase 1
Completed NCT02941042 - A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity. Phase 1
Completed NCT02453711 - Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus Phase 2
Completed NCT02527200 - Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome Phase 3
Completed NCT02958085 - Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight Phase 1
Terminated NCT00665665 - Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers Phase 1
Completed NCT04156165 - The Effect of High vs. Moderate Protein Consumption on Human Health N/A
Recruiting NCT03669809 - The Biological Rhythm of Human Metabolite
Completed NCT02079870 - Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo Phase 1
Completed NCT03095807 - Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity Phase 1
Recruiting NCT05785221 - Lifestyle Intervention on Metabolic Homeostasis N/A